Once again, prescription drug is restricted after company got its money

There is good news and bad news about the popular antipsychotic Seroquel. The good news is, after years of pleas from military families, the U.S. Central Command removed the controversial drug from its approved formulary list in March. Doctors now need a waiver to write a prescription for Seroquel in combat zones, reports Military Times, and the Army, The Navy Department are Air Force are also tightening use. The military blew millions of dollars on antipsychotics like Seroquel only to discover they are not effective against post-traumatic stress disorder (PTSD). Oops.

The bad news is Seroquel’s patent has just run out so AstraZeneca got its money’s worth anyway. Once again, government warnings were so late, AstraZeneca was able to squeeze every drop of Seroquel’s average $549 per month cost before a generic appeared. Thank you, regulators; thank you, taxpayers. In fact, the Department of Veterans Affairs spent $125.4 million and the Pentagon $8.6 million on Seroquel in 2009, when health risks were already suspected. By way of comparison, the cost of a F/A-18 Hornet is $94 million.

Last summer, after reports of arrhythmia (irregular heart beat) in 17 people who took more than the recommended doses of Seroquel, the FDA warned that Seroquel and Seroquel XR “should be avoided” in combination with at least 12 other medications because of heart risks, reported the New York Times. The drugs included synthetic opioids like methadone, other antipsychotics, including Geodon and Thorazine, some antibiotics, anti-infectives and heart rhythm drugs. Seroquel should not be used at all by the elderly or by people with heart disease, warned the FDA, said the Times.

Reports of heart risks have trailed Seroquel for years. In 2009, Vanderbilt University’s Wayne Ray, Ph.D, testified at an advisory committee hearing that patients on drugs like Seroquel showed double the risk of a “sudden, fatal, pulseless condition, or collapse.” Ray had just published an article in the New England Journal of Medicine called Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death. Unfazed, the advisory committee recommended approving extended release Seroquel for depression and later that year, for children. The FDA agreed with both recommendations.

In the two years in which the FDA presumably changed its mind about the heart risks and added a serious warning, Seroquel manufacturer AstraZeneca made from $2 billion to $7 billion on the pill.

Seroquel is not the only overhyped, expensive antipsychotic that turned out not to be the wonder drug it was billed as. Risperdal, Abilify, Zyprexa and Geodan have also been aggressively marketed, despite studies that suggest the drug class works no better than older drugs. The Department of Veterans Affairs spent $717 million on Risperdal to treat post traumatic stress disorder in troops in Afghanistan and Iraq over nine years, only to discover it worked no better than a placebo, said a JAMA study last year. Less than two weeks after the damning study, the VA awarded a contract for two million generic Risperdal pills, reported Nextgov. Why let science get in the way of established prescribing habits?

Still, Seroquel has a corruption trail that few other pills can match.

  • An original backer, psychiatrist Richard Borison, was sentenced to a 15-year prison sentence in 1998 for a pay-to-play Seroquel research scheme involving veterans.
  • Seroquel’s U.S. medical director Wayne MacFadden had sexual affairs with two different women involved with Seroquel research, say published reports.
  • A continuing medical education course that promoted Seroquel, “taught” by AstraZeneca staff and psychiatrist Charles Nemeroff (who left Emory University in disgrace after a Congressional investigation for unreported Pharma income), was scrapped by the Accreditation Council for Continuing Medical Education for lacking “sufficient information” about adverse effects and alternative treatments.
  • Chicago psychiatrist Michael Reinstein prescribed Seroquel for over 1,000 Chicago-area Medicaid patients per year, while subsidized by AstraZeneca, at a total cost of $7.6 million to taxpayers, says the Chicago Tribune and Propublica.
  • Florida child psychiatrist Jorge Armenteros was chairman of the FDA committee responsible for recommending Seroquel approvals while a paid AstraZeneca speaker himself, said the Philadelphia Inquirer in 2009.
  • University of Minnesota psychiatry chief and AstraZeneca consultant Charles Schulz termed Seroquel “significantly superior” to older antipsychotics at an American Psychiatric Association meeting, though data revealed it was actually inferior, charged City News.

Many safe drug and military activists are happy to see Seroquel’s new restricted status in combat zones and hoping the services follow suit. The U.S. Central Command still stocks Seroquel for special uses and emergencies on a case-by-case approval but prescription now requires the explicit permission of the command’s surgeon.

But like other controversial drugs, such as Fosamax, Zyprexa, Lipitor and Singulair, warnings and restrictions have come before and even after patent expiration. Fosamax is linked to throat, jaw and heart abnormalities, Zyprexa to glycemic problems, the asthma drug Singulair to suicidal thinking and statins like Lipitor to memory loss and high blood sugar.

Nor is it clear that new Seroquel warnings and concerns are even affecting sales. Despite last year’s FDA’s heart warnings, the military services issued 54,581 prescriptions for Seroquel last year, reports Military Times.

An earlier version of this story appeared on Truthout.org
“Copyright, Truthout.org. Reprinted with permission”

Martha Rosenberg’s first book, “Born with a Junk Food Deficiency,” was recently featured on C-SPAN2’S Book TV.

Print Friendly, PDF & Email

One Response to Once again, prescription drug is restricted after company got its money

  1. Thanks for all of your work on this web page. I am looking forward to reading more of your posts in the future.